Edition:
India

Daiichi Sankyo Co Ltd (4568.T)

4568.T on Tokyo Stock Exchange

2,586JPY
11:14am IST
Change (% chg)

¥33 (+1.29%)
Prev Close
¥2,552
Open
¥2,592
Day's High
¥2,602
Day's Low
¥2,570
Volume
992,700
Avg. Vol
2,125,197
52-wk High
¥2,750
52-wk Low
¥2,192

4568.T

Chart for 4568.T

About

DAIICHI SANKYO COMPANY, LIMITED is a Japan-based holding company mainly engaged in the manufacture and sale of pharmaceuticals. The Company is involved in the research, development, manufacture and sale of pharmaceuticals, as well as the provision of intermediates and basic materials for pharmaceutical producing in Japan, the... (more)

Overall

Beta: 0.86
Market Cap(Mil.): ¥1,831,022.00
Shares Outstanding(Mil.): 709.01
Dividend: 35.00
Yield (%): 2.52

Financials

  4568.T Industry Sector
P/E (TTM): 28.99 29.18 29.98
EPS (TTM): 89.08 -- --
ROI: 3.57 13.62 13.13
ROE: 4.74 14.52 14.27

BRIEF-Daiichi Sankyo announces new analyses

* Daiichi Sankyo Inc announces new analyses of once-daily savaysa (edoxaban) in patients with non-valvular atrial fibrillation to be presented at the acc 66th annual scientific session

13 Mar 2017

BRIEF-Sosei Group unit signs alliance for R & D of new small molecule therapeutic drug with DAIICHI SANKYO COMPANY LIMITED.

* Says its subsidiary Heptares signed an alliance for R & D of new small molecule therapeutic drug with DAIICHI SANKYO COMPANY LIMITED. on March 13

13 Mar 2017

MEDIA-Daiichi Sankyo moves to block Fortis Healthcare stake sale again - Economic Times

- Note: Reuters has not verified this story and does not vouch for its accuracy

28 Feb 2017

BRIEF-EMA recommends approval of Daiichi Sankyo's anticoagulant

* EU Medicines Agency recommends approval Of Daiichi Sankyo's anticoagulant Edoxaban

24 Feb 2017

BRIEF-Daiichi Sankyo and ArQule's carcinoma drug failed in late-stage trial

* Daiichi Sankyo and Arqule announce the completion of the metiv-hcc phase 3 study of tivantinib in second-line treatment of met-overexpressing hepatocellular carcinoma

17 Feb 2017

BRIEF-Daiichi Sankyo to close Japan research unit Asubio Pharma

* Says move aimed at further reorganising its research and development structure Source text for Eikon: Further company coverage: (Reporting By Chris Gallagher)

10 Feb 2017

BRIEF-Daiichi Sankyo initiates phase 1/2 study of novel antibody drug conjugate in patients unresectable breast cancer

* Daiichi sankyo initiates phase 1/2 study of novel antibody drug conjugate u3-1402 in patients with her3-positive metastatic or unresectable breast cancer Source text for Eikon: Further company coverage:

18 Jan 2017

BRIEF-Kite Pharma establishes strategic partnership with Daiichi Sankyo

* Kite Pharma establishes strategic partnership with Daiichi Sankyo to develop and commercialize axicabtagene ciloleucel (kte-c19) in Japan

10 Jan 2017

Kite Pharma partners with Japan's Daiichi for cancer therapy

Kite Pharma Inc said on Monday it partnered with Daiichi Sankyo Co Ltd to develop and commercialize its cancer treatment therapy in Japan, putting the U.S. company in line to receive up to $250 million in payments.

10 Jan 2017

Kite Pharma partners with Japan's Daiichi for cancer therapy

Jan 9 Kite Pharma Inc said on Monday it partnered with Daiichi Sankyo Co Ltd to develop and commercialize its cancer treatment therapy in Japan, putting the U.S. company in line to receive up to $250 million in payments.

10 Jan 2017

More From Around the Web

Earnings vs. Estimates